期刊文献+

老年2型糖尿病血清MMP-9水平与颈动脉内中膜厚度的相关性 被引量:2

Association of serum MMP-9 and carotid intima-media thickness in elderly patients with type 2 diabetes
原文传递
导出
摘要 目的:探讨老年2型糖尿病(T2DM)患者血清基质金属蛋白酶-9(MMP-9)水平与颈动脉内中膜厚度(IMT)的相关性。方法:老年T2DM患者66例,根据IMT分为3组:单纯糖尿病(DM)组18例,IMT增厚组23例,大动脉粥样硬化(AS)斑块组25例,另设老年健康对照组20例。测定血清MMP-9水平。结果:单纯DM组血清MMP-9水平为(576.43±257.93)μg.L-1,显著高于对照组的(387.70±243.71)μg.L-1(P<0.05);IMT增厚组和AS斑块组血清MMP-9水平分别为(694.58±315.26)、(882.74±286.44)μg.L-1,明显高于对照组和单纯DM组(均P<0.05)。结论:血清MMP-9水平升高与老年T2DM患者颈AS的病变程度密切相关。 Objective : To investigated the association of serum matrix metalloproteinase- 9 ( MMP- 9) and carotid intima-media thickness (IMT) in elderly patients with type 2 diabetes mellitus (T2DM). Methods: A total of 66 elderly patients with T2DM were recruited. These patients were further divided into 3 groups according to IMT. 18 cases of DM group, 23 cases of incrassation group and 25 cases of plaque group. 20 elderly healthy controls were selected. Serum level of MMP-9 were determined. Results: The serum MMP-9 in diabetic patients of DM group (576.43 ± 257.93 ) μg·L^-1 were higher than that in healthy controls ( 387.70 ± 243.71 )μg·L^-1 (P 〈 0.05 ). The diabetic patients of incrassation group ( 694.58± 315.26 )μg·L^-1 and plaque group ( 882. 74 ± 286.44 )μg· L^-1 were higher than that in DM group and healthy controls ( P 〈 0. 05 ). Conclusion: The severity of carotid atherosclerosis(AS) in elderly patients with T2DM is closely associated with the increase of serum MMP-9.
作者 鞠巍 时艺珊
出处 《现代医学》 2012年第6期688-690,共3页 Modern Medical Journal
关键词 基质金属蛋白酶-9 动脉粥样硬化 2型糖尿病 颈动脉内中膜厚度 matrix metalloproteinase-9 atherosclerosis type 2 diabetes mellitus carotid intima-media thickness
  • 相关文献

参考文献9

二级参考文献38

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2611
  • 2吕敏,师绿江,史平,康晟,武留信,武阳丰.中老年自然人群脉压和亚临床颈动脉粥样硬化的关联研究[J].中华心血管病杂志,2004,32(12):1139-1142. 被引量:12
  • 3刘军锋,贾克刚,刘运德.基质金属蛋白酶与心脏重构及心肌病理损害的研究进展[J].中华老年心脑血管病杂志,2007,9(7):499-500. 被引量:12
  • 4[1]Dol F, Martin G, Staels B, et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol,2001,38: 395- 405.
  • 5[2]Tsikouris J P, Cox C D. Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy, 2003,23:1141-1152.
  • 6[3]Reno C, Boykiw R, Luisa M, et al. Temporal alterations in mRNA levels for proteinases and inhibitors and their potential regulators in the healing medial collateral ligament. Biochem Biophys Res Commun, 1998,252:757-763.
  • 7[4]Arroyo L H, Lee R T. Mechanisms of plaque rupture:mechanical and biologic interaction. Cardiovas Res,1999,41:369-375.
  • 8[5]Uzui H, Harpf A, Liu M, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation, 2002 , 106:3024-3030.
  • 9[7]Miyazaki M, Takai S. Involvement of angiotensin Ⅱ in development of atherosclerosis. Nippon Rinsho, 2002,60:1904-1910.
  • 10ZAKOPOULOS N A,LEKAKIS J P,PAPAMICHAEL C M,et al.Pulse pressure in normotensives:a marker of cardiovascular disease[J].Am J Hypertens,2001,14(3):195-199.

共引文献36

同被引文献12

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部